Viridian Therapeutics, Inc.
VRDN
$12.38
-$0.43-3.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 302.00K | 302.00K | 302.00K | 288.00K | 288.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 302.00K | 302.00K | 302.00K | 288.00K | 288.00K |
| Cost of Revenue | 249.79M | 250.72M | 172.23M | 172.23M | 170.55M |
| Gross Profit | -249.49M | -250.42M | -171.93M | -171.95M | -170.26M |
| SG&A Expenses | 63.16M | 61.08M | 78.49M | 85.00M | 88.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 337.31M | 299.34M | 283.34M | 251.07M | 238.16M |
| Operating Income | -337.01M | -299.04M | -283.04M | -250.79M | -237.87M |
| Income Before Tax | -308.32M | -269.95M | -257.08M | -228.06M | -218.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -308.32 | -269.95 | -257.08 | -228.06 | -218.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -308.32M | -269.95M | -257.08M | -228.06M | -218.13M |
| EBIT | -337.01M | -299.04M | -283.04M | -250.79M | -237.87M |
| EBITDA | -336.49M | -298.50M | -282.48M | -250.21M | -237.31M |
| EPS Basic | -3.27 | -2.99 | -2.85 | -2.78 | -3.04 |
| Normalized Basic EPS | -2.65 | -2.48 | -2.70 | -2.66 | -2.82 |
| EPS Diluted | -3.27 | -2.99 | -2.85 | -2.78 | -3.04 |
| Normalized Diluted EPS | -2.65 | -2.48 | -2.70 | -2.66 | -2.82 |
| Average Basic Shares Outstanding | 291.67M | 271.43M | 241.06M | 218.29M | 197.69M |
| Average Diluted Shares Outstanding | 291.67M | 271.43M | 241.06M | 218.29M | 197.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |